Saturday 17 October 2026
Export ALNY’s income statement to Excel — free account
Alnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.
231.83
2.20
−0.94%
Follow ALNY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
748.40 | 163.12 | 80.14 | 51.30 |
P/S ratio |
18.67 | 14.03 | 10.26 | 8.37 | |
P/FCF ratio |
270.78 | 111.94 | 68.35 | 49.06 | |
P/Operating CF |
170.75 | 318.51 | 623.66 | 123.10 | |
P/B ratio |
256.27 | 66.01 | 40.89 | 29.70 | |
Price to Tangible BV |
256.27 | 66.01 | 40.89 | 29.70 | |
EV/Sales |
18.15 | 13.51 | 9.79 | 7.89 | |
EV/EBITDA |
181.47 | 90.08 | 52.01 | 35.96 | |
EV/Operating CF |
219.12 | 95.77 | 58.71 | 41.59 | |
EV/FCF |
263.17 | 107.85 | 65.24 | 46.25 | |
Quick Ratio |
2.37 | 2.51 | 2.89 | 2.79 | |
Current Ratio |
2.54 | 2.76 | 3.13 | 3.05 | |
Net Debt/EBITDA |
(4.41) | (13.09) | (7.09) | (9.36) | |
Debt/Assets |
21.44% | 20.29% | 19.68% | 18.19% | |
Debt/Equity |
4.45 | 1.28 | 0.94 | 0.75 | |
Asset Turnover |
0.71 | 0.81 | 0.92 | 0.95 | |
Operating CF/Net income |
1.40 | 1.07 | 0.34 | 1.99 | |
Capex/Depreciation |
(0.88) | (1.72) | (1.61) | (2.50) | |
Interest Coverage |
8.29 | 1.49 | 3.88 | 2.82 | |
Research and Development Expense of Revenue |
28.73% | 33.93% | 31.26% | 32.00% | |
Selling, General and Administrative Expense of Revenue |
25.79% | 29.66% | 27.64% | 26.95% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.66% | 6.53% | 6.01% | 6.71% | |
Graham Net Nets |
(0.01) | 0.00 | 0.00 | 0.01 | |
Graham Number |
4.94 | 18.18 | 27.42 | 36.58 | |
Earnings Yield |
0.13% | 0.61% | 1.25% | 1.95% | |
Free Cash Flow Yield |
0.37% | 0.89% | 1.46% | 2.04% | |
Revenue per Share |
9.50 | 8.37 | 8.78 | 9.66 | |
Operating CF per Share |
2.67 | 1.25 | 0.53 | 2.45 | |
Capex per Share |
(0.09) | (0.18) | (0.16) | (0.26) | |
Free Cash Flow per Share |
2.58 | 1.07 | 0.37 | 2.19 | |
Cash per Share |
20.73 | 22.20 | 22.64 | 24.76 | |
Shareholders Equity per Share |
1.78 | 6.02 | 8.09 | 10.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.78 | 6.02 | 8.09 | 10.14 | |
Free Cash Flow |
338.89 | 140.26 | 48.67 | 292.04 | |
Working Capital |
2,397.33 | 2,584.31 | 2,869.83 | 3,107.66 | |
Capital Expenditures |
(12.14) | (23.29) | (21.83) | (34.68) | |
Net Current Asset Value |
(664.96) | (126.49) | 165.14 | 415.52 | |
EV/EBIT |
220.08 | 100.07 | 55.80 | 37.93 | |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.03 | |
Price to Operating Income |
226.44 | 103.86 | 58.46 | 40.23 | |
| Other line items | |||||
Average Receivables |
659.31 | 591.44 | 651.00 | 739.93 | |
Average Payables |
94.20 | 102.07 | 112.01 | 105.20 | |
Average Inventory |
75.69 | 80.61 | 74.80 | 84.40 | |
Average Assets |
4,528.35 | 4,603.16 | 4,671.68 | 5,062.39 | |
Average Common Equity |
133.12 | 428.13 | 595.41 | 802.35 |
Columns are period end dates